{"prompt": "['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Laboratory', 'Parameters', 'Assessments', 'pH, glucose, protein, blood, ketones by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', 'Screening', 'Tests', 'childbearing potential only)', 'HIV antibody, hepatitis B surface antigen (HBsAg), and hepatitis C virus', 'antibody\u00b2', 'All study-required laboratory assessments will be performed by a central', 'laboratory', 'NOTES :', '1. Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver', 'stopping or monitoring event are given in Section 8.1 and Appendix 7. All events of ALT >3 X upper', 'limit of normal (ULN) and bilirubin >2 X ULN (>35% direct bilirubin) or ALT >3 X ULN and', 'international normalized ratio (INR) >1.5, if INR measured, which may indicate severe liver injury', \"(possible Hy's Law), must be reported as an SAE (excluding studies of hepatic impairment or\", 'cirrhosis).', '2.', 'Hepatitis C RNA is optional however a confirmatory negative Hepatitis C RNA test must be obtained,', 'to be able to enrol participants with positive Hepatitis C antibody due to prior resolved disease', 'Laboratory results that could unblind the study will not be reported to investigative sites', 'or other blinded personnel until the study has been unblinded.', '60']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.3.', 'Appendix 3: Study Governance Considerations', 'Regulatory and Ethical Considerations', 'This study will be conducted in accordance with the protocol and with:', 'Consensus ethical principles derived from international guidelines', 'including the Declaration of Helsinki and Council for International', 'Organizations of Medical Sciences (CIOMS) International Ethical', 'Guidelines', 'Applicable ICH Good Clinical Practice (GCP) Guidelines', 'Applicable laws and regulations', 'The protocol, protocol amendments, ICF, Investigator Brochure, and other', 'relevant documents (eg, advertisements) must be submitted to an IRB/IEC by', 'the investigator and reviewed and approved by the IRB/IEC before the study is', 'initiated.', 'Any amendments to the protocol will require IEC/IRB approval before', 'implementation of changes made to the study design, except for changes', 'necessary to eliminate an immediate hazard to study participants.', 'The investigator will be responsible for the following:', 'Providing written summaries of the status of the study to the IRB/IEC', 'annually or more frequently in accordance with the requirements, policies,', 'and procedures established by the IRB/EC', 'Notifying the IRB/IEC of SAE or other significant safety findings as', 'required by IRB/IEC procedures', 'Providing oversight of the conduct of the study at the site and adherence to', 'requirements of 21 CFR, ICH guidelines, the IRB/IEC, European', 'regulation 536/2014 for clinical studies (if applicable), and all other', 'applicable local regulations', 'Financial Disclosure', 'Investigators and sub-investigators will provide the sponsor with sufficient, accurate', 'financial information as requested to allow the sponsor to submit complete and accurate', 'financial certification or disclosure statements to the appropriate regulatory authorities.', 'Investigators are responsible for providing information on financial interests during the', 'course of the study and for 1 year after completion of the study.', '61']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Informed Consent Process', 'The investigator or his/her representative will explain the nature of the study to', 'the participant or his/her legally authorized representative and answer all', 'questions regarding the study.', 'Participants must be informed that their participation is voluntary. Participants', 'or their legally authorized representative will be required to sign a statement of', 'informed consent that meets the requirements of 21 CFR 50, local regulations,', 'ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA)', 'requirements, where applicable, and the IRB/IEC or study center.', 'The medical record must include a statement that written informed consent was', 'obtained before the participant was enrolled in the study and the date the written', 'consent was obtained. The authorized person obtaining the informed consent', 'must also sign the ICF.', 'Participants must be re-consented to the most current version of the ICF(s)', 'during their participation in the study.', \"A copy of the ICF(s) must be provided to the participant or the participant's\", 'legally authorized representative.', 'Participants who are rescreened are required to sign a new ICF.', 'The ICF may contain a separate section that addresses the use of remaining', 'mandatory samples for optional exploratory research in accordance with SOP-', 'GSKF-410. The investigator or authorized designee will explain to each', 'participant the objectives of the exploratory research. Participants will be told that', 'they are free to refuse to participate and may withdraw their consent at any time', 'and for any reason during the storage period. A separate signature will be required', \"to document a participant's agreement to allow any remaining specimens to be\", 'used for exploratory research. Participants who decline to participate will not', 'provide this separate signature.', 'Data Protection', 'Participants will be assigned a unique identifier by the sponsor. Any participant', 'records or datasets that are transferred to the sponsor will contain the identifier', 'only; participant names or any information which would make the participant', 'identifiable will not be transferred.', 'The participant must be informed that his/her personal study-related data will be', 'used by the sponsor in accordance with local data protection law. The level of', 'disclosure must also be explained to the participant.', 'The participant must be informed that his/her medical records may be examined', 'by Clinical Quality Assurance auditors or other authorized personnel appointed', 'by the sponsor, by appropriate IRB/IEC members, and by inspectors from', 'regulatory authorities.', '62']\n\n###\n\n", "completion": "END"}